Saturday, April 08, 2023 6:26:59 PM
You are right, Matt Williams is a Novocure proponent.
April 2, 2022
Oncologist Dr Matt Williams, who runs the UK’s only clinic to offer Optune – privately – at Charing Cross Hospital in West London, says: ‘We need to be absolutely clear: this treatment works, it’s not a cure, but it makes people live longer. The reason NICE didn’t recommend it is purely an economic decision.’
Each Optune device is, in effect leased from the company, which provides one-on-one support throughout treatment – a package that adds up to a prohibitive £20,000 a month.
‘Drug companies set a price for new treatments, and Novocure has done the same,’ explains Dr Williams.
‘Some of this will be fixed costs, for manufacture and maintenance of the device, and the salary of the support worker. But as with drugs, the company will be looking to make back money they’ve ploughed into research, development and marketing.
‘It’s just too expensive for the NHS, I understand that. But it’s tough, as a clinician, to know there is an effective treatment that I basically can’t tell my patients about because no one can afford it.
‘The company needs to go back to the negotiating table with a lower price. I’m hopeful this will happen.’
https://www.dailymail.co.uk/health/article-10679311/NHS-refuses-fund-mother-twos-brain-tumour-zapper-not-cost-effective.html
I don't think Prof. Susan Short is a huge DCVax-L advocate.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
